Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

.5 million as compared to $7.4 million in the same period in 2008.

Amicus recorded revenue during the second quarter of 2009 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the second quarter of 2009, Amicus recognized $0.7 million of the Shire upfront payment and $4.7 million of research revenue on reimbursed research and development costs.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3 and are primarily due to pre-tax stock compensation expense.

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per common share exclude the impact of the stock option expense recorded in accordance with SFAS No. 123R. Amicus believes that excluding the impact of expensing stock options better reflects the recurring economic characteristics of its business.

Conference Call and Webcast'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Cereal grain scientists, quality regulators, ... October 5–8, 2014, for the AACC International (AACCI) ... in Providence, Rhode Island. The comprehensive scientific program ... scientists, chemists, microbiologists, nutritionists, and those interested in ... To date, 1,000 attendees have registered for the ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... 2014 Research and Markets has ... Industry Report 2014" report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... human albumin market analysis is provided for the international ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... Jan. 28 Ther-Rx Corporation, a,subsidiary of KV ... KV Pharmaceutical Company on January 26, 2009, a ... lots within,expiration) as a precautionary measure because they ... sufficiently comply with current Good,Manufacturing Practices (cGMPs). , ...
... Product is Japan,s first second-generation drug-eluting stentNATICK, Mass., ... BSX ) announced today that it has ... Labor and Welfare (MHLW) to market its TAXUS(R) ... plans to launch the product as soon as ...
... NOVATO, Calif., Jan. 28 BioMarin Pharmaceutical,Inc. (Nasdaq: ... BioMarin, will host a conference call and webcast on,Wednesday, February ... quarter,and full year 2008 financial results. , , ... International Dial-in Number: 617.213.8835, Participant ...
Cached Biology Technology:Ther-Rx Corporation Issues Nationwide Voluntary Recall of Products 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 3BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET) 2
(Date:9/19/2014)... Oklahoma biology professor will study the unique bioelectric signaling ... eventually benefit people,s health. The OU researcher is ... required to produce the signals used to map the ... at a rate of 500-600 discharges a second throughout ... electric fish are extreme, but necessary for survival. , ...
(Date:9/19/2014)... of fairness did not evolve for the sake of ... benefits of continued cooperation, so say Frans de Waal, ... article about inequity aversion (IA), which is defined as ... published in Science . , Their conclusion ... studies to address their hypothesis that it is the ...
(Date:9/19/2014)... 2014 Nxt-ID, Inc. (Nasdaq: NXTD and ... the growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ... and light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... star Katey Sagal have been cast in Bleed ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... them get psyched up for contests, but when these ... gobble down before and during events, they could be ... treatments for the symptoms of an injury, not the ... University focuses on musculoskeletal health and sports medicine. "They ...
... A University of Maryland School of Medicine researcher will ... nation,s most prominent scientists in the field of stem ... and Preventive Medicine, was chosen by the National Heart, ... of this consortium of national experts, which will be ...
... , , ... Dec. 2 Communication Intelligence Corporation ("CIC") (OTC Bulletin ... for business process automation in the financial industry* and ... Systems Inc. ("Docubase"), a leading International Electronic Document Management ...
Cached Biology News:NSAIDs: Take 'em early and often when competing? Think again 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4
... These skirted micro test tubes are ... of polypropylene, these tubes have uniform walls ... nonsterile, with separate O-ring screw caps. The ... and have an operating range from -55 ...
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... to introduce its new line of Protein ... proteins for use in mass spectrometry, molecular ... Protein Standards are high quality purified proteins ... analyses by electrospray ionization mass spectrometry (ESI-MS). ...
Determin interaction of your protein with Echelons lipids...
Biology Products: